The $58B Weight Loss Drug Market in One Chart

What We're Showing

Weight loss drugs have surged in popularity in recent years, transforming the pharmaceutical landscape. This visualization, created in partnership with Inigo Insurance, highlights the top brands dominating the $58 billion weight loss drug market—and the powerhouse companies driving their success.

Key Takeaways

• In the U.S., roughly 1 in 8 adults (12%) have tried GLP-1 drugs, and 6% are currently using them.
• Despite the range of brand names, the market is dominated by just two companies: Eli Lilly in the U.S. and Denmark’s Novo Nordisk.
• Novo Nordisk leads with Ozempic, which commands nearly one-third of the market (31.5%), followed by Eli Lilly’s Mounjaro at 23.4%.